Biogen
Preço: 200.05Empresa e modelo de negócios
Biogen is a biotechnology company focused on discovering, developing, and delivering innovative therapies for neurological diseases. Its core products include treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Major business segments encompass neuroscience and rare diseases, with primary revenue sources derived from product sales and royalties. The company is recognized for its research and development efforts in the healthcare sector.
Perfil de investimento
The investment profile of Biogen is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income. Its moderate volatility suggests a balanced risk approach, suitable for investors with a medium to long-term horizon.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 9.37 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- 8.7% ↑
- Surpresa de EPS
- 17.0% melhor que o esperado
- Volatilidade 20d
- 1.8% estável
Impacto da previsão
positivoAcompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-05-28 02:36 | Manter | Comprar | Strong EPS growth and positive momentum indicators. |
| 2026-05-20 02:36 | Comprar | Manter | Mixed performance; cautious outlook amid market uncertainty. |
| 2026-05-08 15:04 | — | Comprar | Strong EPS growth and positive momentum indicators. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-06-08 10:32 | Needham | Rating elevado | — → 255 | 195.34 |
| 2026-05-27 09:42 | RBC Capital | Preço-alvo elevado | — → 227 | 193.08 |
| 2026-05-15 10:33 | Piper Sandler | Preço-alvo elevado | 214 → 225 | 191.37 |
Nada ainda